| human | Q5 |
| P2456 | DBLP author ID | 18/3992 |
| P227 | GND ID | 1217869190 |
| P496 | ORCID iD | 0000-0002-7684-0079 |
| P3829 | Publons author ID | 1693461 |
| P1053 | ResearcherID | D-3702-2011 |
| P1153 | Scopus author ID | 23667678400 |
| P214 | VIAF ID | 8578160062462635790000 |
| P735 | given name | ??? | Q4926472 |
| ??? | Q4926472 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q114076979 | PDATK |
| Q114077003 | PharmacoGx |
| Q114077553 | ToxicoGx |
| Q114077620 | Xeva |
| Q114076453 | genefu |
| Q114077511 | survcomp |
| Q35812711 | 4-IBP, a sigma1 receptor agonist, decreases the migration of human cancer cells, including glioblastoma cells, in vitro and sensitizes them in vitro and in vivo to cytotoxic insults of proapoptotic and proautophagic drugs |
| Q33352632 | A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all? |
| Q33861620 | A fuzzy gene expression-based computational approach improves breast cancer prognostication |
| Q35690609 | A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets |
| Q35534413 | A network model for angiogenesis in ovarian cancer |
| Q35769036 | A three-gene model to robustly identify breast cancer molecular subtypes |
| Q36344543 | ABC: a tool to identify SNVs causing allele-specific transcription factor binding from ChIP-Seq experiments |
| Q35156922 | APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation |
| Q40661065 | Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis |
| Q24644185 | Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer |
| Q33692066 | An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets |
| Q57660126 | Analysis of Array Data and Clinical Validation of Array-Based Assays |
| Q28732124 | Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer |
| Q39734181 | Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials |
| Q28597117 | Assessment of pharmacogenomic agreement |
| Q48276812 | Author Correction: Gene isoforms as expression-based biomarkers predictive of drug response in vitro. |
| Q31122464 | BatchQC: interactive software for evaluating sample and batch effects in genomic data |
| Q57660183 | Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes |
| Q112298514 | Biological and therapeutic implications of a unique subtype of NPM1 mutated AML |
| Q36966923 | CD4⁺ follicular helper T cell infiltration predicts breast cancer survival |
| Q38835904 | CD73 is associated with poor prognosis in high-grade serous ovarian cancer |
| Q36991010 | CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer |
| Q34466023 | CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma |
| Q35655229 | Characterization and clinical evaluation of CD10+ stroma cells in the breast cancer microenvironment |
| Q36675500 | Characterization of Conserved Toxicogenomic Responses in Chemically Exposed Hepatocytes across Species and Platforms. |
| Q35610374 | Chromosomal instability as a prognostic marker in cervical cancer |
| Q57660150 | Classification Models for Breast Cancer Molecular Subtyping: What is the Best Candidate for a Translation into Clinic? |
| Q26859166 | Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer |
| Q37039879 | Comparison and validation of genomic predictors for anticancer drug sensitivity |
| Q33362164 | Comparison of prognostic gene expression signatures for breast cancer |
| Q57660188 | Computational Intelligence in Clinical Oncology: Lessons Learned from an Analysis of a Clinical Study |
| Q57462218 | Consensus on Molecular Subtypes of High-Grade Serous Ovarian Carcinoma |
| Q57660064 | Consensus on Molecular Subtypes of Ovarian Cancer |
| Q33974305 | Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response |
| Q49766826 | Corrigendum: Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach |
| Q93086929 | Creating reproducible pharmacogenomic analysis pipelines |
| Q49832760 | CrosstalkNet: A visualization tool for differential co-expression networks and communities |
| Q36038847 | DNA methylation profiling reveals a predominant immune component in breast cancers. |
| Q34542213 | DNA replication stress: a source of APOBEC3B expression in breast cancer |
| Q23760721 | Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach |
| Q42510471 | Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade |
| Q92237808 | Dr.VAE: improving drug response prediction via modeling of drug perturbation effects |
| Q54535173 | Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. |
| Q30405622 | Enhancing reproducibility in cancer drug screening: how do we move forward? |
| Q96431251 | Epigenetic switch-induced viral mimicry evasion in chemotherapy resistant breast cancer |
| Q37690018 | Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype |
| Q40006970 | Evidence of galectin-1 involvement in glioma chemoresistance |
| Q35453467 | Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer |
| Q35667722 | Extensive rewiring of epithelial-stromal co-expression networks in breast cancer |
| Q34153290 | Functional and genetic analysis of the colon cancer network |
| Q37165859 | Galectin 1 proangiogenic and promigratory effects in the Hs683 oligodendroglioma model are partly mediated through the control of BEX2 expression |
| Q24652481 | Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer |
| Q37207766 | Gene expression profiling reveals differences in microenvironment interaction between patients with chronic lymphocytic leukemia expressing high versus low ZAP70 mRNA |
| Q42635307 | Gene isoforms as expression-based biomarkers predictive of drug response in vitro. |
| Q54516947 | Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. |
| Q38264465 | Gene regulatory networks and their applications: understanding biological and medical problems in terms of networks |
| Q35630836 | GeneSigDB: a manually curated database and resource for analysis of gene expression signatures |
| Q40274876 | Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer. |
| Q36171157 | Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients |
| Q37278382 | Genomic grade index is associated with response to chemotherapy in patients with breast cancer |
| Q92821194 | IL6 Induces an IL22+ CD8+ T-cell Subset with Potent Antitumor Function |
| Q39024434 | Importance of collection in gene set enrichment analysis of drug response in cancer cell lines. |
| Q33501853 | Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues |
| Q57660206 | In Reply |
| Q34541198 | Inconsistency in large pharmacogenomic studies |
| Q30791224 | Inference and validation of predictive gene networks from biomedical literature and gene expression data |
| Q38897002 | Integrative Cancer Pharmacogenomics to Infer Large-Scale Drug Taxonomy |
| Q92380366 | Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts |
| Q39989272 | Knocking down galectin 1 in human hs683 glioblastoma cells impairs both angiogenesis and endoplasmic reticulum stress responses |
| Q34105361 | Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression |
| Q33588294 | Long-term temozolomide treatment induces marked amino metabolism modifications and an increase in TMZ sensitivity in Hs683 oligodendroglioma cells |
| Q33816920 | Loss of Pgc-1α expression in aging mouse muscle potentiates glucose intolerance and systemic inflammation |
| Q33697985 | Low CD10 mRNA expression identifies high-risk ductal carcinoma in situ (DCIS). |
| Q45993441 | Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer. |
| Q39858199 | MM2S: personalized diagnosis of medulloblastoma patients and model systems |
| Q57293727 | MYC Interacts with the G9a Histone Methyltransferase to Drive Transcriptional Repression and Tumorigenesis |
| Q35099027 | Medulloblastoma subgroups remain stable across primary and metastatic compartments |
| Q36955113 | Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures |
| Q36998227 | MicroRNA paraffin-based studies in osteosarcoma reveal reproducible independent prognostic profiles at 14q32. |
| Q33769803 | Minimising immunohistochemical false negative ER classification using a complementary 23 gene expression signature of ER status |
| Q90316116 | Modeling Cellular Response in Large-Scale Radiogenomic Databases to Advance Precision Radiotherapy |
| Q36739364 | Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions |
| Q54473138 | Molecular profiling of CD3-CD4+ T cells from patients with the lymphocytic variant of hypereosinophilic syndrome reveals targeting of growth control pathways. |
| Q46579411 | Multifactorial approach to predicting resistance to anthracyclines |
| Q34083912 | Multiple-input multiple-output causal strategies for gene selection |
| Q33556923 | NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML |
| Q41867119 | Network statistics of genetically-driven gene co-expression modules in mouse crosses |
| Q37297706 | Noncoding somatic and inherited single-nucleotide variants converge to promote ESR1 expression in breast cancer. |
| Q57660119 | Novel Effects of Chromosome Y on Cardiac Regulation, Chromatin Remodeling, and Neonatal Programming in Male Mice |
| Q46593271 | Nucleolus and c-Myc: potential targets of cardenolide-mediated antitumor activity |
| Q39177005 | Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality |
| Q114612603 | Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer |
| Q91150412 | Organoid Cultures as Preclinical Models of Non-Small Cell Lung Cancer |
| Q33933172 | PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer |
| Q38874298 | Personalized diagnosis of medulloblastoma subtypes across patients and model systems |
| Q112637653 | PharmacoDB 2.0: improving scalability and transparency of in vitro pharmacogenomics analysis |
| Q38812641 | PharmacoGx: an R package for analysis of large pharmacogenomic datasets. |
| Q33337206 | Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen |
| Q39018410 | Predictive approaches for drug combination discovery in cancer |
| Q35631178 | Predictive networks: a flexible, open source, web application for integration and analysis of human gene networks |
| Q36629530 | Prognostic microRNAs modulate the RHO adhesion pathway: A potential therapeutic target in undifferentiated pleomorphic sarcomas |
| Q37690351 | Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers |
| Q28596241 | Public data and open source tools for multi-assay genomic investigation of disease |
| Q57660210 | Quantification of ZAP70 mRNA in B Cells by Real-Time PCR Is a Powerful Prognostic Factor in Chronic Lymphocytic Leukemia |
| Q42737035 | Quantitative assessment and validation of network inference methods in bioinformatics |
| Q114612602 | REFLECTions on Combination Therapies Empowered by Data Sharing |
| Q36820193 | Rac-specific guanine nucleotide exchange factor DOCK1 is a critical regulator of HER2-mediated breast cancer metastasis |
| Q34488635 | Radiomic feature clusters and prognostic signatures specific for Lung and Head & Neck cancer |
| Q36638518 | RamiGO: an R/Bioconductor package providing an AmiGO visualize interface |
| Q41036297 | Relevance of different prior knowledge sources for inferring gene interaction networks |
| Q35206996 | Robust Radiomics feature quantification using semiautomatic volumetric segmentation |
| Q34568149 | Significance analysis of prognostic signatures |
| Q30742291 | Similarity network fusion for aggregating data types on a genomic scale |
| Q34639023 | Stem cell-like gene expression in ovarian cancer predicts type II subtype and prognosis |
| Q44811326 | Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series |
| Q35829697 | Test set bias affects reproducibility of gene signatures |
| Q33477635 | The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial |
| Q37541316 | The gene regulatory network for breast cancer: integrated regulatory landscape of cancer hallmarks |
| Q97524044 | The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma |
| Q57660139 | Time to move forward from “first-generation” prognostic gene signatures in early breast cancer |
| Q34897615 | Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology |
| Q100560289 | Transparency and reproducibility in artificial intelligence |
| Q36661715 | UNBS5162, a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers |
| Q38472582 | Untangling statistical and biological models to understand network inference: the need for a genomics network ontology |
| Q35950215 | Using shRNA experiments to validate gene regulatory networks |
| Q35606351 | ZNF143 provides sequence specificity to secure chromatin interactions at gene promoters |
| Q30611147 | curatedOvarianData: clinically annotated data for the ovarian cancer transcriptome |
| Q34793900 | mRMRe: an R package for parallelized mRMR ensemble feature selection |
| Q34922055 | microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification |
| Q35526651 | survcomp: an R/Bioconductor package for performance assessment and comparison of survival models |
Search more.